These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21309408)

  • 61. [Value of serum P53 antibody as a tumor marker surveillance of colorectal cancer within follow-up after curative resection].
    Shou CC; Huang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Oct; 15(10):1020-2. PubMed ID: 23297459
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer.
    Teras LR; Gapstur SM; Maliniak ML; Jacobs EJ; Gansler T; Michel A; Pawlita M; Waterboer T; Campbell PT
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):219-223. PubMed ID: 29254936
    [No Abstract]   [Full Text] [Related]  

  • 63. Dermokine as a novel biomarker for early-stage colorectal cancer.
    Tagi T; Matsui T; Kikuchi S; Hoshi S; Ochiai T; Kokuba Y; Kinoshita-Ida Y; Kisumi-Hayashi F; Morimoto K; Imai T; Imoto I; Inazawa J; Otsuji E
    J Gastroenterol; 2010 Dec; 45(12):1201-11. PubMed ID: 20652332
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Myofibroblast distribution is associated with invasive growth types of colorectal cancer.
    Takatsuna M; Morohashi S; Yoshizawa T; Hirai H; Haga T; Ota R; Saito K; Wu Y; Seino H; Aoyagi Y; Terai S; Kijima H
    Oncol Rep; 2016 Dec; 36(6):3154-3160. PubMed ID: 27779697
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer.
    Coomber D; Hawkins NJ; Clark M; Meagher A; Ward RL
    J Cancer Res Clin Oncol; 1996; 122(12):757-62. PubMed ID: 8954174
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma.
    Radosavljevic G; Ljujic B; Jovanovic I; Srzentic Z; Pavlovic S; Zdravkovic N; Milovanovic M; Bankovic D; Knezevic M; Acimovic LJ; Arsenijevic N
    Neoplasma; 2010; 57(2):135-44. PubMed ID: 20099977
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multi-panel assay of serum autoantibodies in colorectal cancer.
    Ushigome M; Nabeya Y; Soda H; Takiguchi N; Kuwajima A; Tagawa M; Matsushita K; Koike J; Funahashi K; Shimada H
    Int J Clin Oncol; 2018 Oct; 23(5):917-923. PubMed ID: 29691673
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Myofibroblasts of the muscle layer stimulate the malignant potential of colorectal cancer.
    Takatsuna M; Morohashi S; Yoshizawa T; Hirai H; Haga T; Ota R; Wu Y; Morohashi H; Hakamada K; Terai S; Kijima H
    Oncol Rep; 2016 Sep; 36(3):1251-7. PubMed ID: 27431808
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Serum p53 antibody assay: evaluation in colorectal cancer].
    Hammel P; Soussi T
    Rev Med Interne; 2000 Feb; 21(2):167-73. PubMed ID: 10703073
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Uselessness of Serum p53 Antibody for Detecting Colitis-associated Cancer in the Era of Immunosuppressive Therapy.
    Toritani K; Kimura H; Kunisaki R; Watanabe J; Kunisaki C; Ishibe A; Chiba S; Inayama Y; Endo I
    In Vivo; 2020; 34(2):723-728. PubMed ID: 32111776
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Clinical Significance of Serum p53 Antibody Measurement in Colorectal Cancer Patients].
    Yokomizo H; Yoshimatsu K; Yano Y; Okayama S; Sakuma A; Satake M; Yamada Y; Matsumoto A; Fujimoto T; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Kato H; Naritaka Y
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1301-1303. PubMed ID: 27760967
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mp colorectal cancer should be defined as early colorectal cancer.
    Kitamura K; Nishida S; Yamamoto K; Ichikawa D; Okamoto K; Sawai K; Yamaguchi T; Takahashi T
    Tohoku J Exp Med; 1998 Apr; 184(4):285-93. PubMed ID: 9699244
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of myofibroblasts at the tumor border of invasive colorectal adenocarcinomas.
    Nakayama H; Enzan H; Miyazaki E; Naruse K; Kiyoku H; Hiroi M
    Jpn J Clin Oncol; 1998 Oct; 28(10):615-20. PubMed ID: 9839502
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Changes in serum lipids in patients with colorectal cancer].
    Abaza H; Ghanem A; Jmal A; Harzallah L; Rahal K; Guemira F
    Tunis Med; 2011 Feb; 89(2):147-50. PubMed ID: 21308622
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of serum p53 antibodies in mucosal colorectal cancer and negative conversion after endoscopic resection.
    Takeda A; Nakajima K; Shimada H; Imazeki H; Takayama W; Hayashi H; Yoshimura S; Suzuki T; Ochiai T; Isono K
    J Clin Gastroenterol; 1999 Mar; 28(2):153-4. PubMed ID: 10078825
    [No Abstract]   [Full Text] [Related]  

  • 76. Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
    Nanami T; Hoshino I; Shiratori F; Yajima S; Oshima Y; Suzuki T; Ito M; Hiwasa T; Kuwajima A; Shimada H
    Int J Clin Oncol; 2022 Jan; 27(1):72-76. PubMed ID: 34632560
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Preoperative angiography of colorectal cancer].
    Fujita M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1989 May; 49(5):583-92. PubMed ID: 2798053
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer.
    Yoshida K; Hiwasa T; Ito M; Ushigome M; Takizawa H; Li SY; Zhang BS; Iwadate Y; Funahashi K; Shimada H
    Oncol Lett; 2023 Mar; 25(3):127. PubMed ID: 36844622
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection of serum p53 protein in patients with different gastrointestinal cancers.
    Attallah AM; Abdel-Aziz MM; El-Sayed AM; Tabll AA
    Cancer Detect Prev; 2003; 27(2):127-31. PubMed ID: 12670524
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform.
    Garranzo-Asensio M; Guzmán-Aránguez A; Povedano E; Ruiz-Valdepeñas Montiel V; Poves C; Fernandez-Aceñero MJ; Montero-Calle A; Solís-Fernández G; Fernandez-Diez S; Camps J; Arenas M; Rodríguez-Tomàs E; Joven J; Sanchez-Martinez M; Rodriguez N; Dominguez G; Yáñez-Sedeño P; Pingarrón JM; Campuzano S; Barderas R
    Theranostics; 2020; 10(7):3022-3034. PubMed ID: 32194852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.